FGFR2 and intrahepatic cholangiocarcinoma: In a recent trial [88], the FGFR2 inhibitor BGJ398 was found to be effective for intrahepatic cholangiocarcinoma patients with activating FGFR2 fusions; however, resistance developed after a short response period.